Gilead Sciences (GILD) Stock
Fundamentals
Recent news

Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
GILD

Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
GILD

Gilead Sciences (GILD) Declines More Than Market: Some Information for Investors
Gilead Sciences (GILD) Declines More Than Market: Some Information for Investors
GILD

Genetic discovery yields clues toward reversal of Alzheimer's brain damage
Genetic discovery yields clues toward reversal of Alzheimer's brain damage
GILD
Technical indicators
- RSI 14
- 43.77
- MACD 12/26/9
- 1.27
- EMA 9 of MACD
- 2.12
- MACD histogram
- -0.85
- SMA 50
- $143.20
- Price above SMA 50
- EMA 50
- $144.24
- Price above EMA 50
- SMA 200
- $136.70
- Price above SMA 200
- EMA 200
- $136.36
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of October 2, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 8 analysts
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of $1.86 for this quarter. The company has not yet shared when it is announcing earnings.
% positive news of 10 articles
published over the past 14 days
Latest news

Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
GILD

Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
GILD

Gilead Sciences (GILD) Declines More Than Market: Some Information for Investors
Gilead Sciences (GILD) Declines More Than Market: Some Information for Investors
GILD

Genetic discovery yields clues toward reversal of Alzheimer's brain damage
Genetic discovery yields clues toward reversal of Alzheimer's brain damage
GILD

BMY vs GILD: Which Biotech Stock Looks More Attractive Now?
BMY vs GILD: Which Biotech Stock Looks More Attractive Now?
GILD

Latin America's PAHO-Gilead HIV Prevention Deal Is a Victory for Civil Society, says AHF
Latin America's PAHO-Gilead HIV Prevention Deal Is a Victory for Civil Society, says AHF
GILD

Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know
Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know
GILD

Gilead Expands Lenacapavir Access With New PAHO Deal in Latin America
Gilead Expands Lenacapavir Access With New PAHO Deal in Latin America
GILD

Gilead Accelerates Global Access Planning for Investigational Once-Yearly Lenacapavir for HIV Prevention
Gilead Accelerates Global Access Planning for Investigational Once-Yearly Lenacapavir for HIV Prevention
GILD

Gilead Sciences Sees Yeztugo Powering HIV Growth as Oncology Pipeline Advances
Gilead Sciences Sees Yeztugo Powering HIV Growth as Oncology Pipeline Advances
GILD
About Gilead Sciences
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Daniel Patrick O'Day | Chairman & CEO | 1965 |
| Mr. Andrew D. Dickinson | Executive VP & CFO | 1970 |
| Ms. Johanna Mercier | Chief Commercial & Corporate Affairs Officer | 1970 |
| Dr. Dietmar P. Berger M.D., Ph.D. | Chief Medical Officer | 1969 |
| Ms. Erin E. Burkhart | Senior VP, Controller & Chief Accounting Officer | 1979 |
| Ms. Jacquie Ross C.F.A. | Senior Vice President of Treasury & Investor Relations | — |
| Ms. Keeley M. Cain Wettan | Executive VP, General Counsel of Legal & Compliance and Secretary | 1975 |
| Dr. Linda Slanec Higgins Ph.D. | Senior Vice President of Research, Innovation & Portfolio | 1962 |
| Dr. Flavius Martin M.D. | Executive Vice President of Research | — |
| Ms. Janet Dorling | Senior Vice President of Intercontinental Region & Global Patient Solutions | 1974 |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Technical indicators
- RSI 14
- 43.77
- MACD 12/26/9
- 1.27
- EMA 9 of MACD
- 2.12
- MACD histogram
- -0.85
- SMA 50
- $143.20
- Price above SMA 50
- EMA 50
- $144.24
- Price above EMA 50
- SMA 200
- $136.70
- Price above SMA 200
- EMA 200
- $136.36
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of October 2, 2026. Technical data, not a recommendation.
Analyst views
8 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $123.00
- Average
- $152.00
- High
- $175.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -3.9 | +5.0 | +5.3 | |||||||||
| 2022 | -5.4 | -11.8 | -1.3 | -0.6 | +7.5 | -4.6 | -4.2 | +6.5 | -5.0 | +25.9 | +10.7 | -2.3 |
| 2023 | -1.7 | -4.1 | +4.2 | -1.2 | -5.5 | +1.1 | -0.8 | +1.1 | -2.2 | +6.0 | -4.5 | +4.3 |
| 2024 | -6.0 | -7.8 | +1.3 | -10.5 | -1.9 | +8.2 | +10.8 | +3.3 | +5.2 | +5.8 | +3.4 | -1.8 |
| 2025 | +5.8 | +16.2 | -3.4 | -4.3 | +6.6 | +1.8 | +0.5 | -0.2 | -1.5 | +7.8 | +3.1 | -1.3 |
| 2026 | +16.7 | +4.2 | -7.1 | -6.7 | +2.1 | -3.6 | +3.4 | +11.6 | -0.6 | -1.9 |
Corporate actions
Upcoming
No upcoming corporate actions for GILD



